Compositions and methods for selective elimination and replacement of hematopoietic stem cells

US11744861B2 · kind B2 · utility

Assignee

• Poseida Therapeutics, Inc. · US

Inventors

• Eric M. Ostertag · San Diego, US
• Devon Shedlock · San Diego, US
• Julian Down · Cambridge, US

Key dates

• Filing date: Mar 13, 2018
• Grant date: Sep 5, 2023
• Expiry date: May 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/90
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are methods of eliminating at least on target cell in a subject, comprising administering to the subject an effective amount of a composition comprising a plurality of immune cells, wherein each immune cell of the plurality expresses one or more chimeric ligand receptor(s) (CLR(s)) that each specifically bind to a target ligand on the at least one target cell, wherein specifically binding of the one or more CLR(s) to the target activates the immune cell, and wherein the activated immune cell induces death of the target cell. Exemplary target cells include, but are not limited to, hematopoietic stem cells (HSCs).